OS Therapies releases trial data supporting FDA approval, U.K. and U.S. timelines, and potential eligibility for a valuable ...

The clinical trials market is ripe with opportunities due to rising chronic and rare diseases, advancements in precision ...

The interferon regulatory factor (IRF) family of transcription factors, pivotal for initiating antiviral type I interferon ...

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus ...

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced a business ...

Alumis Inc. ( ($ALMS) ) just unveiled an announcement. On January 6, 2026, Alumis reported positive topline Phase 3 results from its ONWARD1 and ...

The global immunotherapy drugs market is expected to grow from $260.7 billion in 2025 and is projected to reach $467.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% ...

The FDA has approved a pill form of the popular GLP-1 weight-loss medication George Frey/Bloomberg via Getty The U.S. Food and Drug Administration has approved the pill form of Wegovy, the weight-loss ...

Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The ...

LONDON, Dec 23 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab newly approved weight-loss pill version of Wegovy will be a test case for the fast-growing cash-paying consumer market, with plans ...

The weight-loss drug market just got more crowded — and a lot less painful. The FDA on Monday approved a daily pill version of Novo Nordisk’s Wegovy, making it the first oral GLP-1 obesity treatment ...